KPL · NSE
Kwality Pharmaceuticals Limited
₹3,672.3
+0.83% (+₹30.2)
Prev. close
₹3,642.1
Volume
32,185
Delivery %
38.6%
As of
25 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Kwality Pharmaceuticals Limited
Kwality Pharmaceuticals Limited, together with its subsidiary, manufactures finished pharmaceutical formulations in India and internationally. The company offers its products in various dosage forms, including capsules, eye and ear drops, ointments and creams, pouches and sachets, sanitizers, tablets, suppositories, injectable vials and ampoules, liquid orals, lyophilized products, syrups, and various other categories, such as general, beta-lactam, cephalosporins, oncology, biologics, and hormones and specialty injectables. It also provides intermediates, chemicals, extracts, alkaloids, toilet requisites, beverages, and other medical preparations. Kwality Pharmaceuticals Limited was incorporated in 1983 and is based in Amritsar, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Ramesh Kumar Arora
Headquarters
Amritsar
Employees
1,137
Website
kwalitypharma.comExchange
View on NSE ↗Key stats
P/E ratio (TTM)
46.8
EPS (TTM)
₹78.22
Beta (5Y monthly)
0.49
Shares float
24.43 L
EPS · quarter ended Jun 2026
₹24.69
Financial Performance
01 · Financials
Revenue for Mar 2022–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2021 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY22 growth needs FY21 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹262.01 Cr | ₹456.19 Cr | ₹251.03 Cr | ₹307.08 Cr | ₹370.20 Cr | ₹503.06 Cr | |
| EBITDA | ₹30.44 Cr | ₹175.18 Cr | ₹46.55 Cr | ₹61.04 Cr | ₹82.31 Cr | ₹120.27 Cr |
| ₹15.15 Cr | ₹119.99 Cr | ₹19.37 Cr | ₹23.80 Cr | ₹39.85 Cr | ₹67.35 Cr | |
| Diluted EPS | — | — | ₹18.67 | ₹22.93 | ₹38.4 | ₹64.9 |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹166.26 Cr | ₹340.59 Cr | ₹353.63 Cr | ₹394.21 Cr | ₹447.27 Cr | ₹592.21 Cr | |
| — | — | ₹90.26 Cr | ₹98.12 Cr | ₹112.45 Cr | ₹130.70 Cr | |
| Stockholders' equity | — | — | ₹200.52 Cr | ₹224.21 Cr | ₹264.05 Cr | ₹331.60 Cr |
Current assets, Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹41.38 Cr | ₹42.98 Cr | ₹52.72 Cr | ₹16.59 Cr | |
| Investing cash flow | — | — | ₹-48.44 Cr | ₹-26.40 Cr | ₹-28.52 Cr | ₹-34.91 Cr |
| — | — | ₹99.41 L | ₹-17.40 Cr | ₹-14.44 Cr | ₹7.04 Cr | |
| Capital expenditure | — | — | ₹-47.67 Cr | ₹-29.84 Cr | ₹-25.00 Cr | ₹-48.94 Cr |
| End cash position | — | — | ₹3.07 Cr | ₹2.26 Cr | ₹12.02 Cr | ₹73.64 L |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.44 L Cr | ₹1,852.2 | 37.0 | 5.31 | 13.7% | 0.06 | +11.9% | +13.8% |
| Divi's Laboratories Limited | ₹2.55 L Cr | ₹9,619.5 | 87.0 | 15.21 | 15.3% | 0.00 | +12.3% | +63.1% |
| Torrent Pharmaceuticals Limited | ₹1.90 L Cr | ₹4,928.5 | 79.5 | 22.60 | 25.8% | 1.79 | +21.5% | +36.3% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,889 | 62.5 | 13.48 | 20.5% | 0.90 | +15.7% | +16.6% |
| Lenskart Solutions Limited | ₹1.17 L Cr | ₹680.25 | 177.9 | 13.39 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.17 L Cr | ₹1,180.3 | 26.1 | 4.31 | 18.6% | 0.46 | +18.4% | +13.9% |
| Cipla Limited | ₹1.13 L Cr | ₹1,399.7 | 33.1 | 3.28 | 11.3% | 0.02 | +2.1% | -7.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,007 | 100.4 | 20.52 | 16.8% | 0.48 | +22.0% | +123.9% |
| Mankind Pharma Limited | ₹1.02 L Cr | ₹2,500 | 49.0 | 6.25 | 11.7% | 0.39 | +17.0% | -1.2% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,014 | 70.0 | 9.47 | 13.4% | 0.32 | +19.0% | -10.9% |
| Dr. Reddy's Laboratories Limited | ₹99,991.95 Cr | ₹1,201 | 30.5 | 2.65 | 11.4% | 0.21 | +3.2% | -5.8% |
| Kwality Pharmaceuticals Limited | — | ₹3,642.1 | 47.7 | — | 20.3% | 0.39 | +35.9% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Kwality Pharmaceuticals Share Price Today after 8.59% rise
Kwality Pharmaceuticals Ltd. (KPL) share price rose 8.59% to Rs 3,773.95 today, with a market capitalization of Rs 3,606.14 crore. The stock's P/E ratio of 44.49x is higher than the industry median, and its ROE and ROCE also exceed benchmark medians. No specific catalyst for the price increase was identified in the provided data.